Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AVITA Medical (RCEL) EBIT (2018 - 2025)

Historic EBIT for AVITA Medical (RCEL) over the last 8 years, with Q4 2025 value amounting to -$10.4 million.

  • AVITA Medical's EBIT fell 452.95% to -$10.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$42.5 million, marking a year-over-year increase of 2483.88%. This contributed to the annual value of -$42.5 million for FY2025, which is 2484.23% up from last year.
  • Latest data reveals that AVITA Medical reported EBIT of -$10.4 million as of Q4 2025, which was down 452.95% from -$9.2 million recorded in Q3 2025.
  • Over the past 5 years, AVITA Medical's EBIT peaked at -$4.7 million during Q2 2021, and registered a low of -$17.2 million during Q1 2024.
  • For the 5-year period, AVITA Medical's EBIT averaged around -$9.8 million, with its median value being -$9.9 million (2023).
  • As far as peak fluctuations go, AVITA Medical's EBIT skyrocketed by 6387.93% in 2021, and later crashed by 10773.53% in 2023.
  • AVITA Medical's EBIT (Quarter) stood at -$5.9 million in 2021, then rose by 0.69% to -$5.9 million in 2022, then tumbled by 107.74% to -$12.3 million in 2023, then increased by 18.87% to -$10.0 million in 2024, then dropped by 4.53% to -$10.4 million in 2025.
  • Its EBIT stands at -$10.4 million for Q4 2025, versus -$9.2 million for Q3 2025 and -$11.1 million for Q2 2025.